Jade Biosciences, Inc.

Jade Biosciences, Inc. (ticker: JBIO) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of JBIO's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. JBIO reported no tagged revenue in revenue and -$40.37M for the period ending 2026-03-31, with operating cash flow of -$24.08M. Cash and equivalents stood at $55.09M (up 24.6% year-over-year). Total assets of $319.43M exceed total liabilities of $22.97M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

JBIO Risk Flags

Consolidated view of every risk_flag row JBIOhas surfaced across DredgeCap's extractor pipeline (auditor changes, late filings, delistings, going-concern, dilution, etc.). Each row carries a verbatim source_excerpt and links to the source SEC filing on EDGAR.

Category	Severity	Source	Excerpt	EDGAR
Auditor Change	low	10-K · Mar 6, 2026	PCAOB-tagged auditor in 10-K filed 2026-03-06 (accession 0001193125-26-096550) was 'PricewaterhouseCoopers LLP' (PCAOB Firm ID: 238). Prior 10-K filed 2025-03-27 (accession 0001558370-25-003750) was 'KPMG LLP' (PCAOB Firm ID: 185).	view ↗

Related on JBIO

Auditor & opinion →

Source for auditor_change + going-concern flags.

Share-count dilution →

Source for dilution + convertible-debt flags.

Risk-flag rows are produced by DredgeCap's extractor pipeline (lib/extract-auditor-changes, extract-late-filings, etc.). Each row carries a verbatim source_excerpt from the underlying SEC filing — no AI-generated language. Refresh runs daily. Not financial advice.